All News
How do you separate the misinformation in this ecosystem of cash hungry platforms? Check out
@DoctorYasmin's upcoming book: "What the Fact" for tools on how to handle sifting through the nonsense! #ACR21 @RheumNow https://t.co/oroHMakVT6
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
@DoctorYasmin emphasizes our focus should be on:
1 Moral injury, burnout & mental health for providers
2. Providers should make concerted efforts to learn how to communicate in the public space
3. How to institute cultural change
@DrDavidKarp #ACR21 @rheumnow https://t.co/YH7tDeaki3
TheDaoIndex KDAO2011 ( View Tweet)
"We should be thinking about preparedness...if this happens again, what might our role be, how might we best care for patients"
Brilliant keynote from fellow @Cambridge_Uni alumna @DoctorYasmin #ACR21! Inspiring to hear about her journey through medicine (and beyond)! @RheumNow https://t.co/AyoP1S3zmL
Mrinalini Dey DrMiniDey ( View Tweet)
Wonderful keynote lecture by @DoctorYasmin on The Covidization of Rheumatology: What Will or Won’t Change Beyond the COVID-19 Pandemic #ACR21 @RheumNow
Akhil Sood MD AkhilSoodMD ( View Tweet)
Full circle for VEXAS, from breaking at last years ACR to making the year in review for #ACR21 @RheumNow https://t.co/1iGNPvyzQi
Richard Conway RichardPAConway ( View Tweet)
🙋I cannot be alone in saying I do not #ACR21 @RheumNow https://t.co/AxKK03TJHY
Richard Conway RichardPAConway ( View Tweet)
A quick recap slide on VEXAS syndrome presentation. #ACR21 @RheumNow @petercgrayson https://t.co/4x8hBEFWg2
swethaann23 swethaann23 ( View Tweet)
Still like one of those people like me who struggles with the acronym #VEXAS? Here we go!
1⃣Vacuoles, 2⃣E1 enzyme, 3⃣X-linked, 4⃣autoinflammatory, 5⃣somatic
Year in review at #ACR21 @RheumNow
https://t.co/gMgFPF6NcS
Bella Mehta bella_mehta ( View Tweet)
"How can we institute cultural change?" -@DoctorYasmin asks everyone to weigh in.
@DrDavidKarp @ACRhem #ACR21 @rheumnow @PeterHotez @AWIRGROUP #MedTwitter #RheumTwitter
[Quote tweet your answer here]
TheDaoIndex KDAO2011 ( View Tweet)
Michael Brenner, Basic Science Year in review: Auto-antibodies against interferon, present prior to COVID-19, mostly in men and increases with age: increases risk to #COVID19 mortality #ACR21 @RheumNow https://t.co/5sFqcBtStD
Eric Dein ericdeinmd ( View Tweet)
Who would have thought red cells would be so important in SLE? #ACR21 @RheumNow https://t.co/qnPuZUmEjh
Richard Conway RichardPAConway ( View Tweet)
NETosing is now a verb!
Dr. Brenner: #BasicScience #YearinReview #ACR21
IFN sig driven by:
👉nucleic acid from PMNs NETosing
👉IC's containing Ab and nucleic acid
👉pDC's recog nucleic acids, produce type I IFN
risk alleles
👉Erythroid mitochondrial retention👈
@RheumNow https://t.co/dsNRj7oSBK
TheDaoIndex KDAO2011 ( View Tweet)
OK this one is cool. RNA technology used as pro inflammatory in #COVID #vaccinations but paper of RNA vector giving immunetolerance in mouse model of encephalitis. #ACRBest Yr in Review by M Brenner discussion of paper. Double edged sword ⚔️ @RheumNow #ACR21 https://t.co/8sRl351D27
Janet Pope Janetbirdope ( View Tweet)
#ACR21 Year in Review. Caielli et al. showed in some patients with #lupus, red blood cells retained their mitochondria (Mito+ RBCs) and their frequency correlated with disease activity and blood⬆️IFN @RheumNow https://t.co/ZixgAbOWJ0 https://t.co/hkTWE4m7Ph
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
ADVOCATE - Avacopan: C5a inhibitor, promising new therapy for ANCA vasculitis as possible steroid sparing therapy. Non-inferior outcome of remission, sustained remission, relapse wo signif adverse effects. @rheumnow #ACR21 https://t.co/m5zexRpeS8
Eric Dein ericdeinmd ( View Tweet)
#ACR21 #YearinReview
Avacopan: The game changer for ANCA #vasculitis?🧐
🔅Remission at wk 26: Avacopan non-inferior to Pred (72.3% vs. 70.1%, p<0.001)
🔅Sustained remission at wk 56: Avacopan non-inferior to Pred (65.7% vs. 54.9%, p<0.001)
@RheumNow
https://t.co/CpPYVvRoMR https://t.co/QnsZIUQ0uu
Links:
sheila RHEUMarampa ( View Tweet)
👉Voclosporin for SLE: rapid control of proteinuria (50% reduction over 29 days in UPCR w/o high side effects) @rheumnow #YearInReview #ACR21
Are you all starting to use this drug now? It has helped my patients; pretty well tolerated. https://t.co/zqJRsjnV4n
TheDaoIndex KDAO2011 ( View Tweet)
Dr. K Costenbader #ACR21 #YearinReview add-ons Rx:
👉Avacopan for AAV: new oral C5a inh allowed for remission & prevention of relapse, aggressive pred taper https://t.co/39V3LLOYKZ
TheDaoIndex KDAO2011 ( View Tweet)
AURORA 1, Year in Review: Voclosporin as add-on therapy lupus nephritis. Approved in 1/2021 for active lupus nephritis, very positive data @rheumnow #ACR21 https://t.co/rudYD1OC59
Eric Dein ericdeinmd ( View Tweet)
Year in Review #ACR21. How do you feel about JAK inhibitor after one year of new studies and the new FDA warning? @Rheumnow
Eric Dein ericdeinmd ( View Tweet)